Anixa Biosciences is trading 16.23% down at $3.02, with no confirmed company-specific announcement, filing, earnings release, or clinical update explaining the pre-market decline.

  • Closed at $3.60 on August 26, 2026.
  • The S&P 500 is up 0.44% and Nasdaq Composite up 1.02%, so market-wide weakness does not clearly account for the move.
  • Recent company listings show no newer catalyst.